Towards more personalized low-density lipoprotein cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease

Article Cardiac & Cardiovascular Systems

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm

Steven H. J. Hageman et al.

Summary: This study developed and validated a risk score tool, SMART2, for predicting recurrent ASCVD events in patients with established ASCVD. The tool was calibrated for different regions and demonstrated its clinical utility in treatment decision-making.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model Results from a prospective study in 27 countries in the WHO European region-The EURObservational Research Programme (EORP) of the European Society of Cardiology (ESC)

Dirk De Bacquer et al.

Summary: This study aimed to develop a risk model for predicting recurrent cardiovascular events in coronary heart disease patients and validated it using data from European cohorts. The risk model showed good internal and external validity, and could help optimize management strategies for preventing further disease or death.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L. J. Visseren et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab

Ulf Landmesser et al.

Summary: In patients with recent ACS and high LDL-C despite optimized statin therapy, the addition of alirocumab allowed 94.6% to achieve the 2019 European guideline LDL-C goal <1.4 mmol/L, and 85.2% of those with recurrent cardiovascular events to achieve <1.0 mmol/L. In contrast, the addition of ezetimibe to optimized statin therapy was projected to achieve LDL-C <1.4 mmol/L in only 10.6% of patients at baseline.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems